
There are changes and clarifications to definitions that are needed in the 340B program, but that won't likely happen anytime soon in this Congress. In the meantime, various stakeholders should take the time to educate one another on what the program means to them, said Neil Minkoff, MD, chief medical officer of EmpiraMed.




















